Search results
Results from the WOW.Com Content Network
(Reuters) -FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca in the United States and certain other territories after the companies agreed to ...
When looking at the case of FibroGen’s (FGEN) roxadustat, the biotech’s therapy for sufferers of anemia related to chronic kidney disease (CKD), H.C. Wainwright’s Edwin Zhang thinks a repeat ...
The stock of FibroGen (NAS:FGEN, 30-year Financials) is estimated to be possible value trap, according to GuruFocus Value calculation.
No one likes being given the wrong information. Investors reacted in dismay and sent Fibrogen (FGEN) shares deep into the red following the company's embarrassing announcement. The biotech company ...
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F ...
Roxadustat is reported to increase VEGF, a signal protein that can activate tumor growth [8] and also is considered to cause pulmonary hypertension. [9] In phase 3 trial conducted at 29 sites in China, roxadustat treatment was found to cause hyperkalemia, i.e., increase in serum potassium, and metabolic acidosis in patients.
One thing we could say about the analysts on FibroGen, Inc. ( NASDAQ:FGEN ) - they aren't optimistic, having just made... News Flash: 10 Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Earnings Are ...
For premium support please call: 800-290-4726 more ways to reach us